Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Current Assets (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Current Assets readings, the most recent being $52.4 million for Q1 2026.

  • Quarterly Current Assets rose 39.93% to $52.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $52.4 million through Mar 2026, up 39.93% year-over-year, with the annual reading at $60.6 million for FY2025, 35.91% up from the prior year.
  • Current Assets hit $52.4 million in Q1 2026 for DiaMedica Therapeutics, down from $60.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $60.6 million in Q4 2025 and bottomed at $29.7 million in Q1 2023.
  • Average Current Assets over 5 years is $44.7 million, with a median of $44.6 million recorded in 2024.
  • The largest annual shift saw Current Assets skyrocketed 81.11% in 2022 before it crashed 43.51% in 2025.
  • DiaMedica Therapeutics' Current Assets stood at $33.8 million in 2022, then soared by 58.64% to $53.7 million in 2023, then fell by 16.89% to $44.6 million in 2024, then soared by 35.91% to $60.6 million in 2025, then dropped by 13.63% to $52.4 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Current Assets are $52.4 million (Q1 2026), $60.6 million (Q4 2025), and $56.2 million (Q3 2025).